Abstract
Tirzepatide is a novel dual-action peptide that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This unique mechanism offers potentially enhanced weight loss and glycemic control compared to selective GLP-1 agonists. Developed by Eli Lilly, tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for obesity.
Molecular Background
Key structural and pharmacological characteristics:
- Single peptide with balanced agonism at both GLP-1 and GIP receptors
- 39-amino acid peptide with fatty acid modification
- Extended half-life enabling once-weekly dosing
- First-in-class dual incretin agonist
Mechanism of Action
Tirzepatide's dual mechanism provides complementary benefits:
GLP-1 Receptor Effects:
- Glucose-dependent insulin secretion enhancement
- Glucagon suppression
- Delayed gastric emptying
- Central appetite suppression
GIP Receptor Effects:
- Enhanced insulin sensitivity in adipose tissue
- Improved lipid metabolism
- Potential beta-cell protective effects
- Synergistic weight loss enhancement
Clinical Research Summary
Results from SURMOUNT and SURPASS clinical trial programs:
- Weight Loss: Up to 20-22% body weight reduction at highest doses
- HbA1c Reduction: Superior glycemic control vs. semaglutide in head-to-head trials
- Cardiovascular: Improvements in blood pressure, lipids, and inflammatory markers
- SURMOUNT-1: 91% of participants achieved at least 5% weight loss
Dosing Protocols
- Starting Dose: 2.5mg weekly for 4 weeks
- Maintenance Range: 5mg, 10mg, or 15mg weekly
- Maximum Dose: 15mg weekly
- Titration: Increase by 2.5mg every 4 weeks as tolerated
Comparison: Tirzepatide vs Semaglutide
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor Targets | GLP-1 + GIP (dual) | GLP-1 only |
| Avg. Weight Loss | 15-22% | 10-15% |
| HbA1c Reduction | 2.0-2.3% | 1.5-1.8% |
| Max Dose | 15mg weekly | 2.4mg weekly |
| Safety Data | Growing evidence | Extensive documentation |
Safety Profile
Common adverse events similar to GLP-1 agonists:
- Gastrointestinal: Nausea, diarrhea, vomiting, constipation
- Injection Site: Local reactions (mild)
- Hypoglycemia: Rare when used alone, more common with insulin
Serious considerations:
- Thyroid C-cell tumor risk (rodent studies)
- Pancreatitis (rare)
- Gallbladder disease
- Acute kidney injury (dehydration-related)
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Severe gastrointestinal disease
- Pregnancy and lactation
Current Research Status
Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). Ongoing research investigates its effects on heart failure outcomes (SUMMIT trial), NASH/MASH, and obstructive sleep apnea. Head-to-head trials against semaglutide continue to refine clinical guidance.